March 31,
2008 2007
Sales, net $ - $423
Royalties 25 35
License income - 500
Other expanded access program income 2,292 702
Total revenues 2,317 1,660
Operating expenses:
Cost of goods sold - 576
Research and development 5,241 6,105
Selling, general and administrative 1,482 5,382
Realized loss on investments 392 -
Total expenses 7,115 12,063
Operating loss (4,798) (10,403)
Interest income 279 301
Interest expense (354) (151)
Net loss $(4,873) $(10,253)
Basic and diluted net loss per share $(0.04) $(0.10)
Shares used in computing basic and diluted
net loss per share 121,904 101,328
INSMED INCORPORATED
Consolidated Statements of Cash Flows
(in thousands - unaudited)
Three Months Ended
March 31,
2008 2007
Operating activities
Net loss $(4,873) $(10,253)
'/>"/>
SOURCE Insmed Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1.
Insmed Appoints Dennis M. Lanfear to Board Of Directors2.
Insmed Awarded $2.1 Million by Muscular Dystrophy Association3.
Insmed to Appeal Delisting Notification From Nasdaq4.
Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine5.
Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics6.
Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call7.
Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market8.
Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results9.
Insmed Announces Additional Information in Compliance With NASDAQ Rules10.
Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway11.
Insmed to Present at CBI Follow-On Biologics Conference